Takeuchi, Tsutomu
Tanaka, Yoshiya
Tanaka, Sakae
Kawakami, Atsushi
Song, Yeong-Wook
Chen, Yi-Hsing
Rokuda, Mitsuhiro
Izutsu, Hiroyuki
Ushijima, Satoshi
Kaneko, Yuichiro
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
https://doi.org/10.1136/annrheumdis-2019-215164
Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan
https://doi.org/10.1007/s40744-021-00280-5
Funding for this research was provided by:
Astellas Pharma Inc.
Article History
Received: 11 November 2020
Accepted: 18 January 2021
First Online: 3 March 2021